KIMBERLY MULLINS: Open Payments
NPI 1750725636 · DUFFIELD, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,748 in 112 payments from 20 companies in 2025. Trend: 2023 $1,089 · 2024 $1,613 · 2025 $1,748
Food & beverage: $1,748
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $280 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $252 |
| ABBVIE INC. | 20 | $216 |
| Novo Nordisk Inc | 12 | $191 |
| Lilly USA, LLC | 21 | $155 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $144 |
| Abbott Laboratories | 6 | $108 |
| GlaxoSmithKline, LLC. | 4 | $74 |
| Merck Sharp & Dohme LLC | 3 | $58 |
| Lundbeck LLC | 2 | $44 |
Products named: CAPLYTA, AIRSUPRA, MOUNJARO, Kerendia, FREESTYLE LIBRE 3, VRAYLAR, Wegovy, TRELEGY ELLIPTA.
Industry payments across VA — which companies pay providers there.
